FACTORS INFLUENCING ADOPTION OF BLOCKCHAIN TECHNOLOGY IN THE PHARMACEUTICAL SUPPLY CHAIN FOR PREVENTION OF COUNTERFEIT DRUGS: ENVIRONMENTAL PERSPECTIVE

Authors

  • Mr. Mitesh Pillai Research Scholar, Doctor of Business Administration, S P Jain School of Global Management, 1st floor, Kohinoor City Mall, Premier Rd, Kurla, Mumbai, 400070
  • Dr. Dhrupad Mathur Deputy Director, Faculty Management, Associate Professor -IT, S P Jain School of Global Management, Dubai International Academic City, Block 5, PO Box 502345, Dubai-UAE
  • Dr. Mehregan Mahdhavi Professor and Academic Dean, Sydney International school of Technology and commerce, Sydney, NSW 2000, Australia

Keywords:

Blockchain Technology, Counterfeit Drugs, Pharmaceutical Supply Chain

Abstract

In regard to the pharmaceutical supply chain, the estimate of counterfeit medicines account for 10 to 15 percent. In underdeveloped nations, counterfeit pharmaceuticals account for 30 percent of total drug sales. According to the World Health Organization (WHO) [1], Counterfeiting has become one of the world’s largest and fastest growing illegal businesses and, due to increased production and distribution of counterfeit goods and their ability to be produced in large quantities in a short amount of time, annually it is projected to be worth about 600 billion USD according to the International Anti-Counterfeiting Coalition [3]. The high incidence of counterfeit medications entering the global supply chain has long been a source of concern for the pharmaceutical industry. Counterfeit medications are those that are manufactured or labelled falsely to give the impression of being real, according to the WHO [1]. Because they may contain variable quantities of the active pharmaceutical component or are made in uncontrolled and hazardous circumstances, these counterfeit medications can be harmful, if not fatal, to patients' health [4]. In addition to the negative impact on patients, counterfeit drugs have a direct impact on pharmaceutical businesses’ profits and reputations, since they cannibalise real product markets and tarnish brand image and trustworthiness [5]. To protect human health globally, the WHO, with the help of the IMPACT Group, the European Union, and the G8 combined, is determined to accomplish the aim of combating crime with the help of a digital approach such as blockchain technology. The current paper evaluates the sub factors like regulatory/government support, Industry standard, Policies & Law in terms of international regulation, Mutual trust between the stakeholder on the adoption of BCT technology in pharmaceutical supply chain for counterfeit prevention.

Downloads

Download data is not yet available.

References

World Health Organization, “ Substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medical products,” World Health Organization, 2-5, 2016.

H. Julian, S. Philip, and M. Julian, “ Combating the spread of fake drugs in poor countries” in International Policy Conference on e-Health Networking, Applications and Services,Healthcom, 2016.

E. Roxann, D. Lisa, and P. George, “ Anticounterfeiting in the fashion and luxury sectors: Trends and strategies” in Anti-Counterfeiting— A Global Guide, 2013.

Pharmaceutical Security Institute (PSI). Counterfeit situation, 2017.

E.A. Blackstone, J.P. Fuhr Jr, and S. Pociask, “ The health and economic effects of counterfeit drugs” in American Health & Drug Benefits, 7(4), 216, 2014.

L. Norfeldt, J. Botker, M. Edinger, N. Genina, and J. Rantanen, “ Cryptopharmaceuticals: increasing the safety of medication by a blockchain of pharmaceutical products” in Journal of Pharmaceutical Sciences, 108(9), 2838-2841, 2019.

M. Dadkhah, M. Mehraeen, F. Rahimnia, and K. Kimiafar, “ Users’ Perception of Medical Blockchain” in Advanced Pharmaceutical Bulletin, 11(2), 206, 2021.

M. Arumugam, S. Deepa, G.R. Sreekanth, G. Arun, and S. Nilesh, “ Counterfeit drugs prevention using block chain techniques” in IOP Conference Series: Materials Science and Engineering (Vol. 1055, No. 1, p. 012109). IOP Publishing, February 2021.

V.V. llkov, T.V. Lysenko, S.P. Mymyi, S.S. Tuchkov, and I.O. Shekhovtsova, “ Protection of a human, human rights and international practices in counterfeiting medicines: management and administration issues in the globalized environment” in Journal of Complementary Medicine

Research, 11(2), 98-104, 2020.

A. Berke, “ How safe are blockchains? It depends” in Harvard Business Review. [Online]. Available: https://hbr. org/2017/03/how-safe-are-blockchains-it-depends [accessed Aug. 30, 2018].

V. Pashkov, A. Soloviov, and A. Oler, “ Legal aspects of counteracting the trafficking of falsified medicines in the European Union aspekty prawne przeciwdzialania obrotowi podrobio nymi lekami w unii europejskiej,” Wiad Lek, 71(4), 843-849, 2017.

F.Y. Vladimirovich, D.P. Grigorovich, D. Yermolenko, K. Hanna, and V.V. Ilkov, “ Protection of human rights in the context of combating of counterfeiting medicines: theoretical and legal issues of international cooperations” in Indian Journal of Forensic Medicine & Toxicology, 14(4), 2020.

K. Shamsi, K.E. Khorasani, M.J. Shayegan, “ A secure and efficient approach for issuing KYC token as COVID-19 health certificate based on stellar blockchain network” in arXiv, 2020. published online Oct. 5. [Online]. Available: https://dx.doi.org/10.22133/ijwr.2020.250275.1070 (preprint).

A. Celesti, A. Ruggeri, M. Fazio, A. Galletta, M. Villari, and A. Romano, “ Blockchain-based healthcare workflow for tele-medical laboratory in federated hospital IoT clouds,” in Sensors (Basel); 20: 2590, 2020.

H. Xu, L. Zhang, O. Onireti, Y. Fang, W.B. Buchanan, and M.A. Imran, “ BeepTrace: blockchainenabled privacy-preserving contact tracing for COVID-19 pandemic and beyond,” in arXiv; published online May 20, 2020. https://doi.org/10.1109/JIOT.2020.3025953 (preprint).

Downloads

Published

2022-09-30

How to Cite

Pillai, M. M. ., Mathur, D. D. ., & Mahdhavi, D. M. . (2022). FACTORS INFLUENCING ADOPTION OF BLOCKCHAIN TECHNOLOGY IN THE PHARMACEUTICAL SUPPLY CHAIN FOR PREVENTION OF COUNTERFEIT DRUGS: ENVIRONMENTAL PERSPECTIVE. The Journal of Contemporary Issues in Business and Government, 28(3), 881–889. Retrieved from https://cibgp.com/au/index.php/1323-6903/article/view/2422

Issue

Vol. 28 No. 3 (2022): The journal of contemporary issues in business and government

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.